Umbralisib
from OncoPharm Hosted by John Bossaer
Discussing the latest TKI approval, umbralisib, and its familiar toxicity profile. Also, a few final words on a new CAR-T product and a cemiplimab expanded approval.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 13 minutes long.
When was this OncoPharm episode published?
This episode was published on February 11, 2021.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.